JP6990702B2 - 皮質カテコールアミン作動性神経伝達のモジュレーターとして有用な新規アゼチジン誘導体 - Google Patents
皮質カテコールアミン作動性神経伝達のモジュレーターとして有用な新規アゼチジン誘導体 Download PDFInfo
- Publication number
- JP6990702B2 JP6990702B2 JP2019525851A JP2019525851A JP6990702B2 JP 6990702 B2 JP6990702 B2 JP 6990702B2 JP 2019525851 A JP2019525851 A JP 2019525851A JP 2019525851 A JP2019525851 A JP 2019525851A JP 6990702 B2 JP6990702 B2 JP 6990702B2
- Authority
- JP
- Japan
- Prior art keywords
- azetidine
- difluorophenoxy
- trifluorophenoxy
- compound
- phenoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C*c(c(*)c(*)c(**)c1*)c1OC(*)(C1)C*1O Chemical compound C*c(c(*)c(*)c(**)c1*)c1OC(*)(C1)C*1O 0.000 description 10
- VXXACJCOSVCADM-UHFFFAOYSA-N Fc1cc(OC2CNC2)cc(F)c1 Chemical compound Fc1cc(OC2CNC2)cc(F)c1 VXXACJCOSVCADM-UHFFFAOYSA-N 0.000 description 2
- XPZNUEVJOHJOJP-UHFFFAOYSA-N CC1(CN(C)C1)Oc(c(F)c(c(F)c1F)F)c1F Chemical compound CC1(CN(C)C1)Oc(c(F)c(c(F)c1F)F)c1F XPZNUEVJOHJOJP-UHFFFAOYSA-N 0.000 description 1
- USOICRZZLIIPDJ-UHFFFAOYSA-N CC1(CN(C)C1)Oc(c(F)c1F)cc(F)c1F Chemical compound CC1(CN(C)C1)Oc(c(F)c1F)cc(F)c1F USOICRZZLIIPDJ-UHFFFAOYSA-N 0.000 description 1
- KJVDQRCJPVCDOE-UHFFFAOYSA-N CC1(CNC1)Oc(c(F)c1F)cc(F)c1F Chemical compound CC1(CNC1)Oc(c(F)c1F)cc(F)c1F KJVDQRCJPVCDOE-UHFFFAOYSA-N 0.000 description 1
- BBWINVVJSUYNRL-UHFFFAOYSA-N CC1(CNC1)Oc(c(F)c1F)ccc1F Chemical compound CC1(CNC1)Oc(c(F)c1F)ccc1F BBWINVVJSUYNRL-UHFFFAOYSA-N 0.000 description 1
- NBVRIVWKWYQPOR-UHFFFAOYSA-N CC1(CNC1)Oc1cc(F)cc(F)c1F Chemical compound CC1(CNC1)Oc1cc(F)cc(F)c1F NBVRIVWKWYQPOR-UHFFFAOYSA-N 0.000 description 1
- YDAZTLAZNMAOKG-UHFFFAOYSA-N CCCC(CC1)CC1(C)Oc1cccc(F)c1F Chemical compound CCCC(CC1)CC1(C)Oc1cccc(F)c1F YDAZTLAZNMAOKG-UHFFFAOYSA-N 0.000 description 1
- FIZQSJSNHQGDFZ-UHFFFAOYSA-N CCN(C1)CC1(C)Oc(c(F)c1F)cc(F)c1F Chemical compound CCN(C1)CC1(C)Oc(c(F)c1F)cc(F)c1F FIZQSJSNHQGDFZ-UHFFFAOYSA-N 0.000 description 1
- JMICPHOTUOATDI-UHFFFAOYSA-N CCN(C1)CC1(C)Oc1cc(F)cc(F)c1F Chemical compound CCN(C1)CC1(C)Oc1cc(F)cc(F)c1F JMICPHOTUOATDI-UHFFFAOYSA-N 0.000 description 1
- QZFOOSSYBNBUFN-UHFFFAOYSA-N CCN(C1)CC1Oc(c(F)c(c(F)c1)F)c1F Chemical compound CCN(C1)CC1Oc(c(F)c(c(F)c1)F)c1F QZFOOSSYBNBUFN-UHFFFAOYSA-N 0.000 description 1
- TXBJRUTVVYAHQB-UHFFFAOYSA-N CCN(C1)CC1Oc(c(F)c(cc1F)F)c1F Chemical compound CCN(C1)CC1Oc(c(F)c(cc1F)F)c1F TXBJRUTVVYAHQB-UHFFFAOYSA-N 0.000 description 1
- LFUJJUYSCJKXBM-UHFFFAOYSA-N CCN(C1)CC1Oc(c(F)cc(F)c1)c1F Chemical compound CCN(C1)CC1Oc(c(F)cc(F)c1)c1F LFUJJUYSCJKXBM-UHFFFAOYSA-N 0.000 description 1
- YYEWNOHXTGHXAP-UHFFFAOYSA-N CCN(C1)CC1Oc1cc(F)cc(F)c1 Chemical compound CCN(C1)CC1Oc1cc(F)cc(F)c1 YYEWNOHXTGHXAP-UHFFFAOYSA-N 0.000 description 1
- BREYLKUNMGOWRG-UHFFFAOYSA-N CN(C1)CC1Oc(c(F)c(c(F)c1)F)c1F Chemical compound CN(C1)CC1Oc(c(F)c(c(F)c1)F)c1F BREYLKUNMGOWRG-UHFFFAOYSA-N 0.000 description 1
- PJYOHRYBZCZMTB-UHFFFAOYSA-N CN(C1)CC1Oc(c(F)c(cc1)F)c1F Chemical compound CN(C1)CC1Oc(c(F)c(cc1)F)c1F PJYOHRYBZCZMTB-UHFFFAOYSA-N 0.000 description 1
- FZGJFMOIIUUMLP-UHFFFAOYSA-N CN(C1)CC1Oc(c(F)c1F)cc(F)c1F Chemical compound CN(C1)CC1Oc(c(F)c1F)cc(F)c1F FZGJFMOIIUUMLP-UHFFFAOYSA-N 0.000 description 1
- CXKHNPJLANXKGR-UHFFFAOYSA-N CN(C1)CC1Oc1cc(F)cc(F)c1 Chemical compound CN(C1)CC1Oc1cc(F)cc(F)c1 CXKHNPJLANXKGR-UHFFFAOYSA-N 0.000 description 1
- AZEXZRLKWLCQGP-UHFFFAOYSA-N CN(C1)CC1Oc1cccc(F)c1F Chemical compound CN(C1)CC1Oc1cccc(F)c1F AZEXZRLKWLCQGP-UHFFFAOYSA-N 0.000 description 1
- RIWSKJZOSPBYNC-UHFFFAOYSA-N Fc(cc(c(F)c1F)OC2CNC2)c1F Chemical compound Fc(cc(c(F)c1F)OC2CNC2)c1F RIWSKJZOSPBYNC-UHFFFAOYSA-N 0.000 description 1
- GCRKFHHSKNMMCG-UHFFFAOYSA-N Fc(ccc(F)c1F)c1OC1CNC1 Chemical compound Fc(ccc(F)c1F)c1OC1CNC1 GCRKFHHSKNMMCG-UHFFFAOYSA-N 0.000 description 1
- ATDCQWQTHLFVRW-UHFFFAOYSA-N Fc1cc(OC2CNC2)cc(F)c1F Chemical compound Fc1cc(OC2CNC2)cc(F)c1F ATDCQWQTHLFVRW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16199545.1 | 2016-11-18 | ||
| EP16199545 | 2016-11-18 | ||
| PCT/EP2017/079666 WO2018091687A1 (en) | 2016-11-18 | 2017-11-17 | Novel azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019535715A JP2019535715A (ja) | 2019-12-12 |
| JP2019535715A5 JP2019535715A5 (enExample) | 2020-11-12 |
| JP6990702B2 true JP6990702B2 (ja) | 2022-01-13 |
Family
ID=57348567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019525851A Active JP6990702B2 (ja) | 2016-11-18 | 2017-11-17 | 皮質カテコールアミン作動性神経伝達のモジュレーターとして有用な新規アゼチジン誘導体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10875829B1 (enExample) |
| EP (1) | EP3541784B1 (enExample) |
| JP (1) | JP6990702B2 (enExample) |
| CN (1) | CN109963834B (enExample) |
| DK (1) | DK3541784T5 (enExample) |
| ES (1) | ES2962865T3 (enExample) |
| FI (1) | FI3541784T3 (enExample) |
| PL (1) | PL3541784T3 (enExample) |
| PT (1) | PT3541784T (enExample) |
| WO (1) | WO2018091687A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112198237B (zh) * | 2020-05-28 | 2021-08-06 | 扬子江药业集团广州海瑞药业有限公司 | 一种盐酸奈康唑杂质检测控制分析方法 |
| WO2025008506A1 (en) | 2023-07-06 | 2025-01-09 | Integrative Research Laboratories Sweden Ab | 3-(2,3-difluorophenoxy)azetidine, or a pharmaceutically acceptable salt thereof, for use in the treatment and/or prevention of pathological apathy |
| WO2025008504A1 (en) | 2023-07-06 | 2025-01-09 | Integrative Research Laboratories Sweden Ab | Pharmaceutically acceptable salts of 3-(2,3-difluorophenoxy)azetidine and uses thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012509860A (ja) | 2008-11-24 | 2012-04-26 | エヌエスエイビー、フィリアル アヴ ノイロサーチ スウェーデン エービー、スヴェーリエ | 皮質のカテコールアミン作動性神経伝達のモジュレーターとして有用な新規な３−フェニル−アゼチジン誘導体 |
| JP2013519732A (ja) | 2010-02-17 | 2013-05-30 | アムジエン・インコーポレーテツド | 疼痛治療のためのナトリウムチャンネル阻害薬としてのアリールカルボキサミド誘導体 |
| WO2016030310A1 (en) | 2014-08-27 | 2016-03-03 | F. Hoffmann-La Roche Ag | Substituted azetidine derivatives as taar ligands |
| WO2016073420A1 (en) | 2014-11-05 | 2016-05-12 | Dart Neuroscience, Llc | Substituted azetidinyl compounds as glyt1 inhibitors |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1638939A2 (en) * | 2003-06-24 | 2006-03-29 | Neurosearch A/S | Aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| AP2007004047A0 (en) | 2005-01-20 | 2007-06-30 | Pfizer Ltd | Substituted triazole derivatives as oxtocin antagonists |
| WO2007148185A2 (en) | 2006-06-21 | 2007-12-27 | Pfizer Products Inc. | Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors |
| WO2010022055A2 (en) | 2008-08-20 | 2010-02-25 | Amgen Inc. | Inhibitors of voltage-gated sodium channels |
| MX2011005036A (es) | 2008-11-24 | 2011-06-16 | Nsab Af Neurosearch Sweden Ab | Derivados de 3-fenil-3metoxipirrolidina como moduladores de la neurotransmision catecolaminergia cortical. |
| EP2389374A1 (en) | 2009-01-20 | 2011-11-30 | Pfizer Inc. | Substituted pyrazinone amides |
| TWI404721B (zh) | 2009-01-26 | 2013-08-11 | Pfizer | 胺基－雜環化合物 |
| SG195085A1 (en) | 2011-06-07 | 2013-12-30 | Pfizer | Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors |
| KR101273566B1 (ko) | 2011-09-05 | 2013-06-11 | 한국과학기술연구원 | 신규한 아제티딘 유도체 및 이를 함유하는 항우울제 조성물 |
| AP2014007820A0 (en) * | 2012-01-26 | 2014-07-31 | Lundbeck & Co As H | PDE9 inhibitors with imidazo triazinone backbone |
| WO2016185032A1 (en) | 2015-05-20 | 2016-11-24 | Integrative Research Laboratories Sweden Ab | Novel azetidine derivatives useful as modulators of cortical cathecolaminergic neurotransmission |
| CN108026030B (zh) | 2015-09-18 | 2020-10-09 | 正大天晴药业集团股份有限公司 | 一种氘代化合物的制备方法 |
| JOP20190077A1 (ar) * | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
-
2017
- 2017-11-17 WO PCT/EP2017/079666 patent/WO2018091687A1/en not_active Ceased
- 2017-11-17 PL PL17807779.8T patent/PL3541784T3/pl unknown
- 2017-11-17 FI FIEP17807779.8T patent/FI3541784T3/fi active
- 2017-11-17 EP EP17807779.8A patent/EP3541784B1/en active Active
- 2017-11-17 CN CN201780069687.6A patent/CN109963834B/zh active Active
- 2017-11-17 JP JP2019525851A patent/JP6990702B2/ja active Active
- 2017-11-17 PT PT178077798T patent/PT3541784T/pt unknown
- 2017-11-17 ES ES17807779T patent/ES2962865T3/es active Active
- 2017-11-17 US US16/461,086 patent/US10875829B1/en active Active
- 2017-11-17 DK DK17807779.8T patent/DK3541784T5/da active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012509860A (ja) | 2008-11-24 | 2012-04-26 | エヌエスエイビー、フィリアル アヴ ノイロサーチ スウェーデン エービー、スヴェーリエ | 皮質のカテコールアミン作動性神経伝達のモジュレーターとして有用な新規な３−フェニル−アゼチジン誘導体 |
| JP2013519732A (ja) | 2010-02-17 | 2013-05-30 | アムジエン・インコーポレーテツド | 疼痛治療のためのナトリウムチャンネル阻害薬としてのアリールカルボキサミド誘導体 |
| WO2016030310A1 (en) | 2014-08-27 | 2016-03-03 | F. Hoffmann-La Roche Ag | Substituted azetidine derivatives as taar ligands |
| WO2016073420A1 (en) | 2014-11-05 | 2016-05-12 | Dart Neuroscience, Llc | Substituted azetidinyl compounds as glyt1 inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| PT3541784T (pt) | 2023-11-22 |
| CN109963834A (zh) | 2019-07-02 |
| DK3541784T3 (en) | 2023-10-23 |
| WO2018091687A1 (en) | 2018-05-24 |
| EP3541784B1 (en) | 2023-09-13 |
| PL3541784T3 (pl) | 2024-03-11 |
| EP3541784A1 (en) | 2019-09-25 |
| JP2019535715A (ja) | 2019-12-12 |
| ES2962865T3 (es) | 2024-03-21 |
| US10875829B1 (en) | 2020-12-29 |
| DK3541784T5 (da) | 2024-09-16 |
| FI3541784T3 (fi) | 2023-10-02 |
| CN109963834B (zh) | 2023-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3544972B1 (en) | Heteroarylphenoxy benzamide kappa opioid ligands | |
| NO338622B1 (no) | 3-(heteroaryl-oksy)-2-alkyl-1-aza-bicykloalkylderivater som alfa-7-nAChR ligander for terapi av CNS-sykdommer | |
| JP5668177B2 (ja) | 統合失調症の治療のための重水素化１−ピペラジノ−３−フェニルインダン | |
| JP6990702B2 (ja) | 皮質カテコールアミン作動性神経伝達のモジュレーターとして有用な新規アゼチジン誘導体 | |
| EP4144352A1 (en) | 2-amino-5,5-dimethylhexanoic acid derivatives as sortilin modulators for use in the treatment of disease of the central nervous system | |
| JP5716202B2 (ja) | 皮質のカテコールアミン作動性神経伝達のモジュレーターとしての３−フェニル−３−メトキシピロリジン誘導体 | |
| US20250042905A1 (en) | Dihydropyrrolo[3,4-c]pyrazole derivatives and their use in diagnosis | |
| US10287247B2 (en) | Azetidine derivatives useful as modulators of cortical cathecolaminergic neurotransmission | |
| TWI376373B (en) | Crystalline base of a pharmaceutical compound | |
| JP2023507180A (ja) | Ｏｇａ阻害剤化合物 | |
| JP5621087B2 (ja) | 皮質のカテコールアミン作動性神経伝達のモジュレーターとして有用な新規な３−フェニル−アゼチジン誘導体 | |
| HK1245251A1 (en) | Novel azetidine derivatives useful as modulators of cortical cathecolaminergic neurotransmission | |
| CN118027016A (zh) | Parg抑制剂及其制备方法和用途 | |
| JP2010509249A (ja) | 新規な４−アミノ−ピリジン誘導体及びカリウムチャネルモジュレーターとしてのその使用 | |
| WO2025199234A1 (en) | Vmat2 inhibitors and methods of use | |
| CN117820309A (zh) | 一种哌嗪基-杂环化合物及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200928 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200928 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210824 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211025 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20211109 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20211206 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6990702 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |